A task of the invention is to provide an art that inhibits the hemorrhagic activity exhibited by sulfated glycosaminoglycans, as well as a material, a medical material, and a drug that use a sulfated glycosaminoglycan while being free of the hemorrhaging problems caused by sulfated glycosaminoglycans and that can exhibit an excellent therapeutic effect on biological tissues. The present invention relates to an inhibitor of the hemorrhagic activity originating from sulfated glycosaminoglycans, the inhibitor having a cationized chitosan as an active ingredient.

The present invention relates to a method that includes providing a formulation having an isocyanate-functional prepolymer and a curing component comprising an amino-functional aspartic ester of the general formula (I) ##STR00001##
applying the formulation to a cell tissue; and curing the formulation such that the loss of blood (haemostatic) or tissue fluids is staunched or leaks in cell tissues are sealed.

The present invention relates to a method that includes providing a formulation having an isocyanate-functional prepolymer and a curing component comprising an amino-functional aspartic ester of the general formula (I) ##STR00001##
applying the formulation to a cell tissue; and curing the formulation such that the loss of blood (haemostatic) or tissue fluids is staunched or leaks in cell tissues are sealed.

The present invention provides processes for combined applications of making grooves on an implant surface, applying MgO nanoparticles with PMMA cement, restricting the cement movement by PCL nanofiber and tethering biomolecules with PCL nanofiber to enhance mechanical stability and osseointegration of PMMA cement with bone. This is achieved through enhanced osteoconductive properties, roughness, and less viable fracture originating sites at the bone-cement interface. Such combined applications of nanoparticle and nanofiber on the mechanical stability and osseointegration of cemented implant is heretofore unknown, but as provided by the present invention can solve the debonding problem of cemented implant from bone.

The present invention provides processes for combined applications of making grooves on an implant surface, applying MgO nanoparticles with PMMA cement, restricting the cement movement by PCL nanofiber and tethering biomolecules with PCL nanofiber to enhance mechanical stability and osseointegration of PMMA cement with bone. This is achieved through enhanced osteoconductive properties, roughness, and less viable fracture originating sites at the bone-cement interface. Such combined applications of nanoparticle and nanofiber on the mechanical stability and osseointegration of cemented implant is heretofore unknown, but as provided by the present invention can solve the debonding problem of cemented implant from bone.

An adhesive composition is intended to provide the attaching to human skin, comprising a continuous phase and a discontinuous phase of hydrocolloids, with the continuous phase comprising by weight, based on the total weight of the adhesive composition: (i) 1 to 12% by weight of a sequenced polymer of the styrene-isoprene-styrene or styrene-butadiene-styrene type, (ii) (a) 1 to 15% of a polymer of the elastomer butyl type, possibly as a mixture with up to 25% by weight of a polymer of the polyisobutylene type, or (b) more than 10% to 30% of a polymer of the polyisobutylene type, free of polymer of the elastomer butyl type, (iii) 1 to less than 10% of a polymer of the ethylene vinyl acetate type, with the sum of these three types of polymers representing from 10 to 40%.

An adhesive composition is intended to provide the attaching to human skin, comprising a continuous phase and a discontinuous phase of hydrocolloids, with the continuous phase comprising by weight, based on the total weight of the adhesive composition: (i) 1 to 12% by weight of a sequenced polymer of the styrene-isoprene-styrene or styrene-butadiene-styrene type, (ii) (a) 1 to 15% of a polymer of the elastomer butyl type, possibly as a mixture with up to 25% by weight of a polymer of the polyisobutylene type, or (b) more than 10% to 30% of a polymer of the polyisobutylene type, free of polymer of the elastomer butyl type, (iii) 1 to less than 10% of a polymer of the ethylene vinyl acetate type, with the sum of these three types of polymers representing from 10 to 40%.

A system for use in combining two part preparations, such as bone cement, can include a chamber for intermixing liquid and powder components, a container, a vacuum channel, and a filter. The mixing chamber can be configured to hold a non-liquid, polymer powder component of a bone cement. The container can be configured to hold a liquid component of the bone cement. The vacuum channel can direct a partial vacuum to draw the liquid component from the container into the non-liquid component in the mixing chamber to intermix the components and to thereby provide a settable bone cement.

The present disclosure provides a film composed of a polymer mixture, wherein the polymer mixture includes: a hydrophobic composition including polycaprolactone (PCL); and at least one hydrophilic polymer selected from a group consisting of alginate, gelatin, hyaluronic acid, polyvinyl alcohol (PVA), carboxymethyl cellulose (CMC), polyethylene glycol (PEG), collagen, demineralized bone matrix (DBM), bone morphogenetic protein (BMP), albumin, chitosan, fibrin, polyoxyethylene, polyvinylpyrrolidone, wherein the weight ratio of the hydrophobic composition to the hydrophilic polymer is about 1:0.01-100, and wherein the film has the effect of preventing leakage from a surgical wound or a diffuse wound.

The present disclosure provides a film composed of a polymer mixture, wherein the polymer mixture includes: a hydrophobic composition including polycaprolactone (PCL); and at least one hydrophilic polymer selected from a group consisting of alginate, gelatin, hyaluronic acid, polyvinyl alcohol (PVA), carboxymethyl cellulose (CMC), polyethylene glycol (PEG), collagen, demineralized bone matrix (DBM), bone morphogenetic protein (BMP), albumin, chitosan, fibrin, polyoxyethylene, polyvinylpyrrolidone, wherein the weight ratio of the hydrophobic composition to the hydrophilic polymer is about 1:0.01-100, and wherein the film has the effect of preventing leakage from a surgical wound or a diffuse wound.